<p>AstraZeneca Pharma India and Sun Pharma have entered into a partnership for the distribution of dapagliflozin, an innovative type 2 diabetes medicine, in India.<br /><br /></p>.<p>AstraZeneca India markets dapagliflozin under the brand name Forxiga, and under the terms of the agreement, both companies will promote, market and distribute dapagliflozin in India under different brand names. Under the agreement, Sun Pharma will promote and distribute dapagliflozin under the brand name Oxra, while AstraZeneca will retain its intellectual property rights. <br /><br />AstraZeneca India Managing Director Sanjay Murdeshwar said, “AstraZeneca is committed to addressing unmet need in the treatment of Type 2 diabetes by offering treatment options to physicians that meet the needs of individual patients.<br /><br />Dapagliflozin represents a significant advancement in the treatment of Type 2 diabetes and this agreement supports our strategy of working with a local partner to maximize the value from our innovative medicines in a key emerging market. It ensures a greater number of patients will have access to this important treatment option.”<br /><br />AstraZeneca India is currently seeking approval from the Drug Controller General of India for the combination of dapagliflozin with metformin. </p>
<p>AstraZeneca Pharma India and Sun Pharma have entered into a partnership for the distribution of dapagliflozin, an innovative type 2 diabetes medicine, in India.<br /><br /></p>.<p>AstraZeneca India markets dapagliflozin under the brand name Forxiga, and under the terms of the agreement, both companies will promote, market and distribute dapagliflozin in India under different brand names. Under the agreement, Sun Pharma will promote and distribute dapagliflozin under the brand name Oxra, while AstraZeneca will retain its intellectual property rights. <br /><br />AstraZeneca India Managing Director Sanjay Murdeshwar said, “AstraZeneca is committed to addressing unmet need in the treatment of Type 2 diabetes by offering treatment options to physicians that meet the needs of individual patients.<br /><br />Dapagliflozin represents a significant advancement in the treatment of Type 2 diabetes and this agreement supports our strategy of working with a local partner to maximize the value from our innovative medicines in a key emerging market. It ensures a greater number of patients will have access to this important treatment option.”<br /><br />AstraZeneca India is currently seeking approval from the Drug Controller General of India for the combination of dapagliflozin with metformin. </p>
